Home /Research /LBA3 Safety and efficacy of pembrolizumab combined with paclitaxel and cisplatin as a neoadjuvant treatment for locally advanced resectable (stage III) esophageal squamous cell carcinoma (Keystone-001): Interim analysis of a prospective, single-arm, single-center, phase II trial

OTHER

LBA3 Safety and efficacy of pembrolizumab combined with paclitaxel and cisplatin as a neoadjuvant treatment for locally advanced resectable (stage III) esophageal squamous cell carcinoma (Keystone-001): Interim analysis of a prospective, single-arm, single-center, phase II trial

Xianwen Shang, Chao Zhang, Gang Zhao, W. Zhang, L. Liu, Xingyu Duan, J. Yue, Zhao Ma, C. Chen, Bin Meng, Xiubao Ren, Hongjing Jiang

Year: 2021
Citations: 13

Keywords

MedicinePembrolizumabAdverse effectPerioperativeNeoadjuvant therapySurgeryInterim analysisOncologyInternal medicineRadiation therapy

LBA3 Safety and efficacy of pembrolizumab combined with paclitaxel and cisplatin as a neoadjuvant treatment for locally advanced resectable (stage III) esophageal squamous cell carcinoma (Keystone-001): Interim analysis of a prospective, single-arm, single-center, phase II trial

Keywords

Related papers

Statistical Learning Theory

Fractional Differential Equations

Applied Nonlinear Control

Genetic Programming: On the Programming of Computers by Means of Natural Selection